2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Head & Neck
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
3
Lung Neoplasms
3
Carcinoma, Medullary
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Interventions
Carboplatin
345
Cisplatin
240
Paclitaxel
208
Radiotherapy
206
Pemetrexed
190
Docetaxel
170
Gemcitabine
158
pembrolizumab
146
Erlotinib Hydrochloride
111
Magnetic Resonance Spectroscopy
101
Etoposide
98
Bevacizumab
96
Specimen Handling
84
Nivolumab
77
durvalumab
73
Radiosurgery
73
Blood Specimen Collection
65
Drug Therapy
61
osimertinib
56
Vinorelbine
54
Gefitinib
50
Surveys and Questionnaires
48
atezolizumab
44
Biopsy
43
Irinotecan
42
Radiation
41
Topotecan
39
Standard of Care
38
Cyclophosphamide
38
Surgical Procedures, Operative
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
pralsetinib
×
Clear all
NCT06563999
2026-04-21
NUMER
Sun Yat-sen University
Phase 2
Recruiting
120 enrolled
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA